A controlled trial was carried out into the relative efficacy of two beta-blocking agents (oxprenolol and metoprolol) as adjuncts to group therapy in a smoking withdrawal clinic. There was no evidence to indicate that these were of specific value in assisting smoking withdrawal.
Introduction
The Royal College of Physicians (1971, 1977) has indicated that there is 'great need for further investigation into the most effective ways of helping dependent smokers', as in the context of smoking withdrawal clinics. The facilities of such a unit were available for the present study (Fee & Benson 1971 , Fee 1977 , Fee & Stewart 1982 .
It is well known that side effects of varying character and intensity may complicate the process of smoking withdrawal; these include craving, anxiety, depression, lack of concentration, tremor, irritability, sweating and sleep disturbances (Knapp et al. 1963 ). If it is accepted that such manifestations might result from a stressful situation induced by smoking withdrawal, and be maintained by excessive adrenergic stimulation, then it would appear reasonable to suggest that f-blocking agents might be effective in their treatment (Lancet 1973 , Carruthers 1976 , British Medical Journal 1976 fl-blocking agents have varying ancillary properties such as presence of intrinsic sympathomimetic activity (ISA) or the possession of relative cardioselectivity. Selective /3blockers would be expected to have a lesser effect on airways resistance and pulmonary function (potentially, if not actually, impaired in the individual smoker) and thus be more suitable for administration to smokers, but non-selective agents might be more effective in relieving the withdrawal symptom complex because they have effects other than those upon the heart itself.
We have therefore compared the efficacy of two fl-blocking agents, namely a cardioselective (non-ISA) agent, metoprolol (Lopressor), against a non-selective (with ISA) agent, oxprenolol (Trasicor). The objectives of the study were: (1) to assess the value of ,fadrenoceptor blockade in controlling smoking withdrawal symptoms; (2) to assess the value off,-adrenoceptor blockade as an adjunct to group therapy in achieving successful cessation of smoking; (3) to compare the relative efficacy of metoprolol and oxprenolol in achieving objectives (1) and (2).
Methods
Two hundred and seventy-seven smokers were recruited for the trial from a smoking withdrawal clinic waiting list. All received a comprehensive questionnaire to establish whether there was a contraindication to fl-blocker therapy in their histories, and also to establish their smoking habits. Each subject's family doctor was approached and asked to indicate if a contraindication to fl-blocker therapy existed. All subjects not thereby excluded were then examined and any individual with an abnormal pulse rhythm or rate, or peak expiratory flow rate of less than 80% of individual predicted value, was excluded from the trial.
Just over 30% (99 subjects) proved suitable and these were invited to participate. Females outnumbered males (62%: 38%). Age distribution was as follows: > 50 years 26%, 30-49 years 55%, <30 years 18%. Social class III comprised 42%, class II 22% and class IV 14%.
No other selection procedure was employed other than clinical suitability for fl-blocker therapy.
A double-blind controlled trial was then commenced, subjects being allocated into 3 groups (A, B and C) by random selection, to whom a specific medication was allocated using a double-dummy technique as follows: A, oxprenolol 80 mg twice daily + placebo metoprolol; B, placebo oxprenolol + metoprolol 100 mg twice daily; C, placebo oxprenolol +placebo metoprolol. Duration of treatment was 40 days.
A fourth group (D) comprised the subjects unsuitable for fl-blocker administration, numbering 178 in all.
Thereafter, all groups received a standard course of group therapy and health education. At its conclusion, a questionnaire was completed by all participants in which success or failure in cessation of smoking was recorded, and the relative contribution of the various aspects of the course assessed. The subjects who received drug treatment were presented with a list of 23 side effects commonly associated with smoking withdrawal, and were asked to assess the intensity of each symptom on a 6-grade scale varying from 'intolerable' to 'not at all'.
For validation purposes, retiring specimens of urine were taken from all subjects on the first day of treatment and again at discharge. (Due to an unfortunate misadventure, however, samples taken at discharge were not, in fact, processed by the laboratory receiving them.)
The study was approved by the Ethical Committee relevant to the establishment concerned, the Ninewells Hospital and Medical School, University of Dundee.
Results
Of 277 subjects initially assessed, 176 were considered unsuitable for the administration of ,Bblocker therapy. Relative performance of main groups on discharge In Table 1 , subgroups A, B and C receiving medication are presented as one combined group (Group R) for comparison with the group receiving group therapy alone (Group D). Subjects who received medication were more successful in stopping smoking and defaulted less, the difference being statistically significant (P<0.001). Relative performance of groups by method of treatment (Table 2) At discharge, 14 of 31 subjects (45.2%) receiving placebo reported cessation as against 13 of 33 (39.3%) receiving metoprolol, and 11 of 35 (31.4%) receiving oxprenolol. The difference in cessation performance was not significant. R=subjects undergoing medication and group therapy (A, B, C combined) D=subjects treated by group therapy alone However, cessation was more durable in the groups A and B who had received fl-blockers than it proved to be in Group C who had received placebo, this becoming apparent 3 months after discharge, and more distinct at one year when 8 out of 33 (24.2%) in Group B (metoprolol) were still abstinent, compared with 6 out of 35 (17.1%) in Group A (oxprenolol) and only I out of 31 (3.2%) in Group C (placebo). The cessation performance at one year after discharge of those who had taken the placebo was in fact worse than the performance after one year of those in Group D who had received no medication at all. Of 23 potential smoking withdrawal symptoms there was no significant evidence of favourable effect for either metoprolol or oxprenolol.
Conclusion
These re.sults indicate that only a moderate proportion of the smoking population may safely receive fl-blocking drugs, and few seem likely to achieve significant assistance in smoking withdrawal.
Metoprolol and oxprenolol in the doses used were of no value in assisting cessation of smoking by preventing the symptoms commonly associated with, the early phases of smoking withdrawal. No explanation can be offered for the relative reduction in relapse at one year after treatment with either fl-blocking agent.
The relative advantage apparently gained by the group on medication over the group on group therapy alone can be ascribed to a noticeable esprit de corps amongst that group. It is also possible that the group who had been excluded from fl-blockade in this trial because of established cardiorespiratory disease, were more heavily addicted to the smoking habit.
